Benitec Biopharma
BNTC
13 hedge funds and large institutions have $3.9M invested in Benitec Biopharma in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
8% more funds holding
Funds holding: 12 → 13 (+1)
2% more capital invested
Capital invested by funds: $3.84M → $3.9M (+$58.7K)
2.93% less ownership
Funds ownership: 49.72% → 46.8% (-2.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$55.7K |
| 2 |
Morgan Stanley
New York
|
+$34K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.67K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$1.71K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$13 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$210K |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$86K |
| 3 |
MHR
Matthew Hamilton Rosenberg
|
-$70 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Franklin Resources
San Mateo,
California
| $1.91M | – | – | – |
|
|
SCM
2
Suvretta Capital Management
New York
| $660K | – | – | – |
|
3
Adage Capital Partners
Boston,
Massachusetts
| $611K | – | – | – |
|
|
4
Janus Henderson Group
London,
United Kingdom
| $589K | -$86K | -25,771 | -12% |
|
|
5
Vanguard Group
Malvern,
Pennsylvania
| $53.9K | +$55.7K | +16,701 | New |
|
|
6
Morgan Stanley
New York
| $32.9K | +$34K | +10,200 | New |
|
7
Geode Capital Management
Boston,
Massachusetts
| $32.5K | – | – | – |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $8.06K | +$7.67K | +2,299 | +1,173% |
|
|
9
UBS Group
Zurich,
Switzerland
| $2.01K | +$1.71K | +513 | +471% |
|
|
GI
10
GAMMA Investing
Foster City,
California
| $947 | +$1.13K | +337 | New |
|
11
RhumbLine Advisers
Boston,
Massachusetts
| $602 | – | – | – |
|
12
Group One Trading
Chicago,
Illinois
| $288 | – | – | – |
|
|
13
Wells Fargo
San Francisco,
California
| $55 | +$13 | +4 | +31% |
|
|
14
Citadel Advisors
Miami,
Florida
| – | -$210K | -69,515 | Closed |
|
|
MHR
15
Matthew Hamilton Rosenberg
| – | -$70 | -23 | Closed |
|
BNTC Hedge Fund Activity: Q4 2023 in Review
13 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q4 2023, worth a combined $3.9M — up 1.5% from $3.84M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new BNTC positions and 2 closed out — a net gain of 1 holder — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $55.7K. The largest seller was Citadel Advisors, exiting entirely with an estimated $210K sold.
- 13 institutional investors held Benitec Biopharma (BNTC) as of Q4 2023, up from 12 in Q3 2023.
- Funds reported $3.9M of Benitec Biopharma stock for Q4 2023, up 1.5% quarter-over-quarter.
- 3 funds opened new Benitec Biopharma positions in Q4 2023 and 2 closed out, a net change of +1 holder.
- The largest Benitec Biopharma buyer in Q4 2023 was Vanguard Group, an estimated $55.7K added.
- The largest Benitec Biopharma seller in Q4 2023 was Citadel Advisors, an estimated $210K sold.
Based on aggregated 13F filings for Q4 2023.